AB1200 Cognitive impairment associated with S100[beta] protein in childhood-onset systemic lupus erythematosus

Objectives To determine clinical and laboratorial manifestations associated with S100β protein in childhood-onset systemic lupus erythematosus (cSLE) patients Methods We included consecutive cSLE patients with disease onset before the age of 16 and healthy controls and age and healthy age and sex matched controls. All subjects underwent a standardized neuropsychological evaluation assessing the following: simple attention, complex attention, memory, visuospatial processing, language, reasoning/problem solving, psychomotor speed, and executive functions. Individual results were converted into standard scores and compared to normative data. Subjects with a total score in any of the 8 domains ≤-2 SD below the normative value were considered impaired. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory (BDI and BAI) in all subjects. cSLE patients were assessed for disease activity [SLE Disease Activity Index (SLEDAI)], damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)] and current drug exposures. S100β protein levels were measured by enzyme-linked immunosorbent assay using commercial kits. Clinical/laboratorial manifestations, disease activity, cumulative damage and drugs undertaken were assessed at time of blood withdrawal. Results We included 42 cSLE patients (mean age 16.56±3.68) and 20 healthy controls (mean age 19.9±5.31). Cognitive impairment was observed in 25 (60%) cSLE patients and in 3 (15%) healthy controls (p